UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

RNA-Seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature

Chapman, MA; Sive, J; Ambrose, J; Roddie, C; Counsell, N; Lach, A; Abbasian, M; ... Yong, K; + view all (2018) RNA-Seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature. Blood , 132 (20) pp. 2154-2165. 10.1182/blood-2018-05-849893. Green open access

[thumbnail of Yong_RNA seq of newly diagnosed patients in the padimac study leads to a bortezomib or lenalidomide decision signature_AAM.pdf]
Preview
Text
Yong_RNA seq of newly diagnosed patients in the padimac study leads to a bortezomib or lenalidomide decision signature_AAM.pdf - Accepted Version

Download (1MB) | Preview

Abstract

Improving outcomes in multiple myeloma will not only involve development of new therapies, but better use of existing treatments. We performed RNA sequencing (RNA-Seq) on samples from newly diagnosed patients enrolled into the phase II PADIMAC (Bortezomib, Adriamycin, and Dexamethasone (PAD) Therapy for Previously Untreated Patients with Multiple Myeloma: Impact of Minimal Residual Disease (MRD) in Patients with Deferred ASCT) study. Using synthetic annealing and the Large-Margin-Nearest-Neighbor algorithm, we developed and trained a seven-gene signature to predict treatment outcome. We tested the signature on independent cohorts treated with bortezomib- and lenalidomide-based therapies. The signature was capable of distinguishing which patients would respond better to which regimen. In the CoMMpass (relating Clinical outcomes in Multiple Myeloma to personal assessment of genetic profile) dataset, patients who were treated correctly according to the signature had a better progression-free survival (median 20.1 months versus not reached; hazard ratio 0.40; confidence interval 0.23-0.72; p=0.0012) and overall survival (median 30.7 months versus not reached; hazard ratio 0.41; confidence interval 0.21-0.80; p=0.0049) than those who were not. Indeed, the outcome for these correctly treated patients was non-inferior to those treated with combined bortezomib, lenalidomide, and dexamethasone, arguably the standard of care in the United States, but not widely available elsewhere. The small size of the signature will facilitate clinical translation, thus enabling more targeted drug regimens to be delivered in myeloma.

Type: Article
Title: RNA-Seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1182/blood-2018-05-849893
Publisher version: https://doi.org/10.1182/blood-2018-05-849893
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > CRUK Cancer Trials Centre
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Cancer Bio
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation
URI: https://discovery.ucl.ac.uk/id/eprint/10057036
Downloads since deposit
58Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item